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Abstract 
The use of the recombinant expression platform Pichia pastoris to produce pharmaceutically important proteins has 
been investigated over the past 30 years. Compared to mammalian cultures, expression in P. pastoris is cheaper and 
faster, potentially leading to decreased costs and process development times. Product yields depend on a number 
of factors including the secretion signal chosen for expression, which can influence the host cell response to recom-
binant protein production. VRC01, a broadly neutralising anti-HIV antibody, was expressed in P. pastoris, using the 
methanol inducible AOX1 promoter for both the heavy and light chains. Titre reached up to 3.05 μg mL−1 in small 
scale expression. VRC01 was expressed using both the α-mating factor signal peptide from Saccharomyces cerevisiae 
and the murine IgG1 signal peptide. Surprisingly, using the murine IgG1 signal peptide resulted in higher yield of 
antibody capable of binding gp140 antigen. Furthermore, we evaluated levels of secretory stress compared to the 
untransformed wild-type strain and show a reduced level of secretory stress in the murine IgG1 signal peptide strains 
versus those containing the α-MF signal peptide. As bottlenecks in the secretory pathway are often the limiting factor 
in protein secretion, reduced levels of secretory stress and the higher yield of functional antibody suggest the murine 
IgG1 signal peptide may lead to better protein folding and secretion. This work indicates the possibilities for utilising 
the murine IgG1 signal peptide for a range of antibodies, resulting in high yields and reduced cellular stress.
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Introduction
Over the last 30  years the methylotrophic yeast Pichia 
pastoris has been used to produce heterologous recombi-
nant proteins with over 5000 different proteins expressed 
to date (Ahmad et al. 2014). The engineering of a human-
ized glycosylation strain has meant that in addition to 
enzymes and basic proteins, more complex proteins can 
be produced with increased efficacy over alternative 
yeast recombinant expression systems such as Saccharo-
myces cerevisiae (Jacobs et al. 2009; Hamilton and Gern-
gross 2007). Some such proteins are antibodies, which 
require the correct glycosylation patterns in order to fold 
and function correctly.
The anti-HIV broadly neutralising antibody (bNAb), 
VRC01, has been used in a Phase I clinical trial ending 
August 2015 (NIAID 2013) and in April 2016 two phase II 
clinical trials (the AMP studies) were announced to eval-
uate the safety and efficacy of bNAb VRC01 in prevent-
ing HIV-1 infection in high-risk, HIV uninfected women 
and men and transgender people who have sex with 
men (NIAID 2015, 2016). Most commonly expressed in 
human embryonic kidney cells (HEK), this bNAb was 
originally isolated from patient serum. It neutralizes 
approximately 90% of circulating viral isolates at IC50 of 
50 μg mL−1, although this value falls to 70% at 1 μg mL−1 
(Wu et al. 2010). VRC01 actively binds to the HIV enve-
lope glycoprotein gp140, blocking its interaction with 
CD4+ receptor on T cells and is particularly effective as 
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it directly mimics the structure of the CD4+ receptor (Li 
et al. 2011).
There are several advantages of using P. pastoris as 
an expression host. It grows to very high cell densities, 
leading to exceptionally high volumetric productivity. 
In addition, P. pastoris secretes very few native proteins, 
making downstream processing of secreted products sig-
nificantly easier. In most instances proteins are fused to 
the α-mating factor (α-MF) signal peptide from S. cerevi-
siae to target proteins to the secretory pathway. However, 
there has been extensive research indicating that this is 
not always the best option (Lin-Cereghino et  al. 2013; 
Damasceno et al. 2012) and optimisation of secretion sig-
nals can significantly increase the titre obtained. Native 
signal peptides from the protein of interest have also been 
used successfully, such as when expressing the major uri-
nary protein complex (MUP) (Ferrari et  al. 1997; Stadl-
mayr et  al. 2010). Other secretion signals are regularly 
utilised, including non-fungal signals such as the human 
serum albumin signal peptide, which has been shown to 
be effective when producing human lysozyme (Xiong and 
Chen 2008).
Here we evaluated expression with the murine IgG1 
signal peptide, which is often used for protein secre-
tion in mammalian cells (Kabanova et al. 2014; Zuo et al. 
2000) and has been successfully transferred to antibody 
expression in Leishmania tarentolae and plant based 
systems (Klatt and Konthur 2012; Chen et  al. 2015). 
Active VRC01 antibody was successfully produced in P. 
pastoris and the murine IgG1 signal peptide resulted in 
higher secretion yields than using the α-MF signal pep-
tide. As the secretory pathway has often been attrib-
uted as the bottleneck when secreting proteins (Love 
et al. 2012; Ferrer-Miralles et al. 2009; Delic et al. 2013; 
Mattanovich et  al. 2004), it was of interest that strains 
expressing VRC01 with the murine IgG1 signal peptide 
show reduced secretory stress, indicating that this may 
be preferential for the secretion of VRC01 and possibly 
for antibodies in general.
Materials and methods
Media and growth conditions
Bacterial strains were cultured in Lennox lysogeny 
broth (LB) medium (1% peptone au casein, 0.5% yeast 
extract, 0.5% NaCl) and supplemented with either 
100 μg mL−1 Zeocin™ (Thermo Fisher Scientific, Paisley, 
UK) or 100  μg  mL−1 ampicillin (Sigma Aldrich, Dorset, 
UK). Yeast strains were cultured in a rich YPD medium 
(2% peptone au casein, 1% yeast extract, 2% dextrose). 
Selection was carried out using Zeocin and Nourseo-
thricin (clonNAT; Jena Bioscience, Jena, Germany) at 
100 μg mL−1 each. Expression was carried out in buffered 
glycerol/methanol-complex medium (BMGY/BMMY; 1% 
yeast extract, 2% peptone, 100 mM potassium phosphate, 
pH 6.0, 1.34% yeast nitrogen base, 4 ×  10−5% d-Biotin, 
1% glycerol or 0.5% methanol).
Strain construction
Bacterial recombinant DNA manipulation was car-
ried out in Escherichia coli strain NEB 5-α (New Eng-
land Biolabs, Hertfordshire, UK). The VRC01 heavy and 
light chain genes were generated from their published 
sequence (Wu et  al. 2010) and cloned into a pUC19 
vector already containing the murine IgG1 secretion 
signal (Tiller et  al. 2008). The amino acid sequence of 
the murine IgG1 secretion signal is GWSCIILFLVA-
TATGVHSQ. The four vectors used in this study were 
constructed using the DNA Gibson Assembly method 
(Gibson et al. 2009). Initially the VRC01 heavy and light 
chains were amplified by PCR using Phusion® High-
Fidelity DNA polymerase (New England Biolabs) ensur-
ing that the murine IgG1 secretion signal was included 
and primers designed to add regions of homology to 
the relevant vectors. The VRC01 heavy chain gene was 
integrated into the pPICZ A vector (Thermo Fisher Sci-
entific). The VRC01 light chain gene was integrated into 
the pJAN-1 vector (Biogrammatics, Carlsbad, USA). A 
second set of vectors were made with the initial ampli-
fication of VRC01 removing the murine IgG1 secre-
tion signal for integration into the pPICZα A vector and 
pJAN-s1 vector (both containing the α-MF signal peptide 
from S. cerevisiae), which were also amplified with the 
relevant regions of homology. The PCR fragments were 
gel extracted using the Zymoclean™ Gel DNA Recovery 
kit (Zymo Research Corporation, Irvine, USA). DNA was 
incubated at 50 °C in equimolar concentrations of 100 ng 
of DNA with the ingredients of the Gibson master mix 
(Gibson et al. 2009) and 1 μL was transformed into NEB 
5-α competent cells (New England Biolabs).
For cloning into P. pastoris 5–10  μg of plasmid DNA 
was linearised with PmeI at a single restriction site within 
the AOX1 promoter. The vectors were transformed into 
cells by electroporation according to recommenda-
tions in the Pichia Expression manual (Thermo Fisher 
Scientific) into the P. pastoris strain Δku70 (CBS 12694, 
CBS-KNAW, Fungal Biodiversity Centre, Utretch, The 
Netherlands) and grown for 3–5  days at 30  °C on YPD 
medium containing 100 μg mL−1 Zeocin (Thermo Fisher 
Scientific) and 100 μg mL−1 Nourseothricin (Jena Biosci-
ence) to select for double transformants.
Colony PCR
Colony PCR of P. pastoris was performed by boiling a 
sample of the transformed colony in 20 μL of 20  nM 
NaOH for 15  min. 2 μL of this solution was used as a 
template for a PCR reaction using Phire HotStart II as 
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described in the manufacturer’s instructions. Primers for 
the heavy chain were TCA GAT GAA GAA GCC TGG 
CGA G and GTC CAC CTT GGT GTT GCT GG and for 
the light chain TGA CAC AGT CTC CAG GCA CC and 
CTG TTG AAG CTC TTT GTG ACG G.
Protein expression
Screening expression in P. pastoris was performed in 
24 deep-well plates in 3 mL of medium and sealed with 
Breathe-Easy® sealing membrane (Sigma Aldrich). Flask 
expression in P. pastoris was performed in 500 mL glass 
baffled flasks in 50 mL of medium. Cells were incubated 
at 30  °C, 216  rpm for 24  h in BMGY to allow growth 
before being centrifuged at 4000  rpm for 5  min. The 
supernatant was removed and the medium replaced 
with BMMY to induce expression. Cultures were left to 
express at 20 °C, 216 rpm for 72 h before being harvested. 
Every 24 h the culture was supplemented with 0.5% (v/v) 
methanol.
Dot blot analysis
The Bio-Dot® Apparatus (Bio-Rad) was used according 
to manufacturer’s instructions. 50 μL of sample superna-
tant from the deep-well plate expression was loaded into 
individual wells. A vacuum was applied until all the liquid 
had passed through the membrane. The VRC01 antibody 
was detected by using a 1:2000 dilution of an AP-conju-
gated Rabbit Anti-Human IgG H&L (Abcam, Cambridge, 
UK). Spots were developed using the alkaline phosphate 
substrate BCIP/NBT kit (Thermo Fisher Scientific).
Protein analysis
Sodium dodecyl sulfate polyacrylamide gel electropho-
resis (SDS–PAGE) was performed using 12% mini-PRO-
TEAN® TGX™ precast gels (Bio Rad, Hemel Hempstead, 
UK). P. pastoris culture supernatants were denatured 
by boiling for 5 min in either reducing or non-reducing 
SDS sample buffer (0.0625  M Tris–HCl, pH 6.8, 2.3% 
(w/v) SDS, 10% (w/v) glycerol and 0.01% Bromophenol 
blue. ±  5% (v/v) β-mercaptoethanol). Molecular weight 
was estimated by using a prestained protein ladder 
(10–170  kDa, Thermo Fisher Scientific). Transfer to an 
Immobilon®-FL PVDF membrane (Millpore (U.K) Ltd, 
Herfordshire, UK) was performed using a Novex® semi-
dry blotter (Thermo Fisher Scientific). VRC01 antibody 
was detected by using a 1:5000 dilution of an AP-con-
jugated Rabbit Anti-Human IgG H&L (Abcam). Bands 
were developed using the alkaline phosphate substrate 
BCIP/NBT kit (Thermo Fisher Scientific).
Enzyme‑linked immunosorbent assay (ELISA)
ELISA was performed on neat supernatant cultures from 
flask expression. For the total Ig ELISA, Nunc Maxisorp 
(Thermo Fisher Scientific) high-binding 96-well micro-
plates were coated with 100 μL anti-human Kappa and 
Lambda light chain mix (Southern Biotech, Birmingham, 
USA) in PBS at 4  °C overnight. Wells were washed with 
0.05% (v/v) Tween in PBS four times, and subsequently 
blocked with 200 μL 0.05% (v/v) Tween and 1% (v/v) 
Bovine Serum Albumin (BSA) in PBS for 1  h at 37  °C. 
To generate a standard curve 50 μL standard antibody 
in fivefold serial dilution was added to triplicate wells, 
with a starting concentration of 1000 ng mL−1. The plates 
were then incubated for 1 h at 37 °C, washed, and 100 μL 
detection antibody added (anti-human IgG HRP; South-
ern Biotech), diluted to 1:10,000 in 0.05% (v/v) Tween 
and 1% BSA in PBS. After 1 h incubation at 37  °C wells 
were washed a further 4 times. 50 μL TMB (KPL Inc, 
Milford, USA) was added and incubated for 5 min. 50 μL 
of Stop solution (KPL Inc) was added and the absorbance 
measured at 450 nm immediately. To determine antigen-
specific binding wells were coated with 50 μL CN54-
gp140 antigen at 1 μg mL−1 in PBS at 4 °C in place of the 
IgG capture antibodies.
Copy number analysis
Copy number analysis was performed as previously 
described (Aw and Polizzi 2016) with minor differences 
detailed below. Quantitative PCR was run on genomic 
DNA using KICStart® SYBR® Green qPCR ReadyMix™ 
(Sigma Aldrich) in an Eppendorf Mastercycler® ep real-
plex quantitative cycler (Eppendorf UK Ltd, Histon, UK). 
Copy number of the heavy and light chain was calculated 
using a standard curve against known concentrations of 
the pPIC-Heavy and pJan-Light plasmids, respectively. 
Primers for the Heavy chain were AAT CAC AAG CCC 
AGC AAC AC and GGG CAT GTG TGA GTT TTG 
TCA C resulting in a 74  bp amplicon. Primers for the 
Light chain were TGT CTT CAT CTT CCC GCC ATC 
and ATT CAG CAG GCA CAC AAC AG resulting in a 
70 bp amplicon. Cycling conditions were 95 °C for 5 min 
followed by 40 cycles of 95 °C for 5 s, 58 °C for 15 s and 
72 °C for 10 s with a melting curve afterwards to ensure a 
single product was being measured. Error bars were cal-
culated using a Taylor series expansion, which takes into 
consideration the error of the standard curve in addition 
to the deviation between samples (Gerards 1998).
RT‑qPCR
For reverse transcription (RT)-qPCR, RNA was isolated 
using RiboPure-Yeast Kit according to manufacturer’s 
instructions (Applied Biosystems, Warrington, UK). 
Typically 3 × 108 cells were collected, equivalent to 1 mL 
of culture with OD600 of 1. cDNA was prepared using 
the High-Capacity cDNA Archive Kit (Applied Biosys-
tems, Warrington, UK) according to the manufacturer’s 
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instructions. 1 μg RNA was used in a total reaction vol-
ume of 20 μL. RT-qPCR reactions were set up using the 
2× SYBR® Green JumpStart Taq Ready Mix (Sigma-
Aldrich, Dorset, UK). An Eppendorf Mastercycler® ep 
realplex quantitative cycler was used (Eppendorf UK Ltd, 
Histon, UK). Data was analysed using the Pfaffl method, 
based on ΔΔ−Ct (Pfaffl 2001; Livak and Schmittgen 
2001) and normalised to ACT1 as the housekeeping gene. 
Primers for ACT1 were GCT TTG TTC CAC CCA TCT 
GT and TGC ATA CGC TCA GCA ATA CC. Prim-
ers for KAR2 TCA AAG ACG CTG GTG TCA AG and 
TAT GCG ACA GCT TCA TCT GG, for PDI GCC GTT 
AAA TTC GGT AAG CA and TCA GCT CGG TCA 
CAT CTT TG. For HAC1 two primer sets were used, 
one indicating total HAC1 TTC TGG AAA ACC ACG 
TCG TC and TCC AAA TCT GAG ACG GTA CCA C 
and one indicating spliced HAC1 ACA GCT CCA TCA 
GGT TCC ATC and AAT GGT GCT GCA GGA TGA 
T. All samples were normalised to Δku70 before addi-
tion of methanol. Error bars are representative of the 
Gaussian error propagation of the standard deviation of 
s[untreated control], s[treated control], s[untreated sam-
ple] and s[treated sample] (Yuan et  al. 2006). All statis-
tical analysis was conducted in R (R Core Team 2015). 
The student t test was applied with significant variance 
observed where p ≤ 0.05.
Results
Construction of the VRC01 expression strains
To assess the production of the bNAb VRC01 in P. 
pastoris the heavy and light chains were cloned inde-
pendently into the commercial vectors pPICZα and 
pJANs-1, respectively. The α-MF signal peptide is the 
standard sequence used for extracellular expression and 
is included in many of the commercial expression vectors 
available. Therefore, we created vectors where both the 
heavy and light chain genes were fused to the sequence of 
the α-MF signal peptide. Additionally, the murine IgG1 
signal peptide, which is a popular choice in mammalian 
expression systems, was also tested. In total four vec-
tors were generated with a combination of either heavy/
light chain and α-MF/murine signal peptide (Fig. 1). All 
VRC01 antibody chains were expressed using the alcohol 
oxidase 1 (AOX1) promoter.
Vectors were transformed into Δku70 P. pastoris 
using co-transformation and dual selection on both 
100  μg  mL−1 cloNAT and 100  μg  mL−1 Zeocin to inte-
grate both the heavy and the light chains. Both vectors 
integrate into the same locus (AOX1), and therefore by 
using Δku70, which prevents off-target integration, a 
higher proportion of clones with the correct integra-
tion should be observed (Naatsaari et al. 2014). Individ-
ual colonies were selected and the presence of both the 
Fig. 1 Graphical representation of vector generation. Four vectors were generated containing a combination of either the VRC01 heavy chain or 
light chain and either the α-MF or murine IgG1 signal peptide. All vectors utilised the AOX1 promoter for expression
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heavy and light chains within the P. pastoris genome was 
confirmed by colony PCR (Additional file  1: Figure S1). 
Clones containing the α-MF signal peptide are referred 
to as α and those containing the murine IgG1 signal pep-
tide are referred to as M in the subsequent sections.
Expression of VRC01 antibody in P. pastoris
To analyse expression, 18 single colonies from both α and 
M transformations were inoculated in 3 mL of BMGY in 
24 deep-well plates and grown for 24  h in BMGY prior 
to induction using the methanol containing medium 
BMMY. Wild-type Δku70 was subjected to the expres-
sion conditions and analysed as a control. Cultures were 
left to express for 72 h at 20 °C due to the complexity of 
the protein to aid folding and assembly. Dot blot analysis 
was used to determine qualitatively whether the VRC01 
was expressed into the supernatant (Fig. 2). The dot blot 
results show that on average supernatant from the α 
strains contains a higher concentration of VRC01 anti-
body than the M strains.
Based on the dot blot results, two clones that expressed 
a high level of the VRC01 antibody were selected from 
both the α and M strains for expression in shake flasks. 
Copy number analysis was carried out to ensure the 
strains analysed were of similar copy number (Addi-
tional file 2: Figure S2). α1 has one copy of both the heavy 
and light chains, while α2 and M1 have 2 copies of the 
heavy chain and 1 of the light chain and M2 has two cop-
ies of both the heavy and light chains (Additional file 2: 
Figure S2). The four strains were inoculated into 50 mL 
BMGY and grown for 24 h shaking at 30 °C. After 24 h, 
the culture supernatant was removed, and the medium 
replaced with BMMY. Cultures were expressed for a total 
of 72 h, feeding an additional 0.5% (v/v) methanol every 
24  h. At 0, 2, 4 and 6 RNA samples were collected and 
after 72 h the supernatant was collected for analysis.
The dot blot is a qualitative analysis, which does not 
give an indication of whether the protein is correctly 
folded or functional. Therefore, ELISA was undertaken 
to quantify the yield of intact antibody (Fig. 3) and West-
ern blots were performed under both reducing and non-
reducing conditions to observe the ratio of heavy and 
light fragments (Additional file 3: Figure S3). The ELISA 
procedures for both total IgG1 and gp140 binding anti-
body concentration measurements require both the 
heavy and light chain to be expressed for a signal to be 
detected, unlike the dot blot which only requires either 
of the chains to be present. Total IgG1 antibody yield 
(Fig.  3a) ranged from 0.09 (α2) to 3.05  μg  mL−1 (M2). 
The M1 and M2 strains showed significantly higher total 
antibody yield (2.45 and 3.05 μg mL−1, respectively) than 
the α1 and α2 strains (0.81 and 0.09  μg  mL−1, respec-
tively). The discrepancy between the ELISA measure-
ments and the dot blot results could be the result of an 
imbalance between the amount of light and heavy chain 
secretion as it has been previously shown that light 
chain can be secreted on its own (Gasser et  al. 2006; 
Gach et al. 2007; Lee et al. 1999). Since the copy number 
of α2 and M2 are the same (Additional file 2: Figure S2) 
the differences in yield cannot be a result of differences 
in copy number.
It was noticeable that within the subset groups (α and 
M), α1 shows significantly higher (p = 0.0068) titre com-
pared to α2, despite having lower copy number of the 
heavy chain (Additional file  2: Figure S2). However, M2 
showed significantly higher yield (p = 0.0373) than M1, 
and in this instance M2 had the higher copy number. This 
implies that having more than one copy of each of the 
genes for heavy and light chains does not cause secretion 
saturation (Hohenblum et al. 2004) and the differences in 
yield observed cannot be accounted for by copy number 
alone. Despite the individual differences among the α and 
M strains, the strains containing the murine IgG1 signal 
peptide had a volumetric productivity three times higher 
the best strain utilising the α-MF signal peptide.
From the Western blot results it is clear that α2 shows 
significantly less expression than the other strains (Addi-
tional file  3: Figure S3). Furthermore, the non-reducing 
gel (Additional file  3: Figure S3b) shows a strong signal 
at 55 KDa, particularly in the α1 strain, which could be 
excess heavy chain or dimerized light chain. This may 
explain the reduced yields in the ELISA results (Addi-





Fig. 2 Expression of VRC01 light and heavy chain in P. pastoris deter-
mined by dot blot. Dot blot was used to confirm the expression of 
the VRC01 from culture supernatants using a Rabbit Anti-Human IgG 
heavy and light antibody conjugated to alkaline phosphatase. 1–6 
culture supernatants; a–c—α-MF strains, d–f—murine IgG1 strains. 7a 
Δku70, 7b–f blank
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Additionally, an ELISA was run using the gp140 antigen, 
giving an indication of active antibody (Fig. 3b). Here the 
results between M1 and M2 were not significantly dif-
ferent (p = 0.219) with M1 at 75.489 ng mL−1 and M2 at 
105.32 ng mL−1. Levels of gp140 specific antibody from α2 
were undetectable, indicating there may have been a prob-
lem with the folding and/or secretion of the antibody in 
this specific strain. Levels of antibody capable of binding to 
gp140 for α1 are also significantly lower than both M1 and 
M2 (p = 0.0300 and 0.0401, respectively) at 1.53 ng mL−1. 
Therefore, in addition to higher total antibody concentra-
tion, specific antigen binding antibody titres were higher 
for both murine IgG1 signal peptide strains.
UPR signalling and secretory stress
To ascertain whether the differences in yield between 
strains were due to secretory stress, RT-qPCR was used 
to analyse gene expression levels of UPR related genes. 
We analysed KAR2, PDI1 and HAC1 looking at both 
total HAC1 and spliced HAC1. Samples were taken at 
0 h (pre-induction) and then 2, 4 and 6 h post-induction. 
All samples were compared to the untransformed Δku70 
wild-type strain at 0 h (Fig. 4a–d).
After induction with methanol all strains show upregu-
lation of the UPR markers investigated except for PDI1. 
This includes upregulation of UPR markers in the wild-
type strain, which has been previously observed as a 
result of the switch to methanol, which requires large-
scale cellular reorganisation to produce the required per-
oxisomes (Vanz et al. 2012; Edwards-Jones et al. 2015).
HAC1 splicing (Fig.  4a) is commonly used as an indi-
cator of UPR induction, as the spliced variant is trans-
lated into the transcription factor responsible for UPR 
propagation after binding the UPR elements (UPRE) 
(Guerfal et  al. 2010). From 4  h, all strains expressing 
VRC01 show consistently higher levels of spliced HAC1 
suggesting rapid UPR activation. Interestingly, at 4 h M1 
and M2 show a higher degree of HAC1 splicing than α1 
and α2, suggesting some UPR response is beneficial to 
cells (Gasser et al. 2008).
Spliced HAC1 RNA is translated into a functional 
transcription factor, which activates the expression of 
UPR target genes include the folding chaperones KAR2 
and PDI1 (Mattanovich et al. 2004). In addition, the pro-
moter region of HAC1 also contains UPRE and therefore 
total HAC1 levels are also an indicator of UPR signalling 
(Guerfal et  al. 2010). For KAR2 (Fig.  3b) after 4 h there 
appears to be a significant upregulation in α2, M1 and 
M2 compared to the wild-type strain. The α1 strain does 
not show significant upregulation of KAR2, although 
RNA levels are elevated at 6 h. This suggests that α1 has 
a lower UPR response than the other three strains, which 
may be due to the fact that it has single copies of the 
heavy and light chain genes.
Interestingly, for PDI1 expression (Fig.  4c), at 2  h all 
strains showed a significant downregulation compared to 
Δku70 at 0  h, a trend that was also observed for KAR2 
expression. Although co-expression of chaperones such 
as PDI1 along with a protein of interest has often been 
shown to have mixed results in improving recombinant 
protein yield (Inan et al. 2006; Aw and Polizzi 2013), some 
PDI1 activation would be expected because the promoter 
region contains UPRE. While the lack of upregulation is 
puzzling, the fact that the other UPR markers, including 
spliced HAC1 are upregulated, strongly indicates that the 
UPR is activated.
Fig. 3 Concentration of total antibody and gp140 specific antibody. ELISA was used to determine concentration of total IgG1 antibody and gp140 
specific antibody (n = 3). a Total IgG1 antibody. b gp140 specific antibody
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As mentioned above, total HAC1 levels can also be 
considered a marker of UPR. Even before induction total 
HAC1 levels in α2, M1 and M2 showed significantly 
higher expression compared to Δku70 at 0  h (Fig.  4d). 
The AOX1 promoter is not known to have leaky expres-
sion when grown in shake flasks (Aw and Polizzi 2016), 
even though this is not the case for bioreactors (Bawa 
et  al. 2014). Therefore, this implies that there may be 
other stresses on α2, M1 and M2, such as the onset of 
starvation. Interestingly, 2 h after induction with metha-
nol, levels of total HAC1 return to baseline. However, 
after 4  h of expression all the strains producing VRC01 
once again show a significant upregulation of total HAC1 
levels compared to wild-type. Total HAC1 levels remain 
elevated in all strains, except for α1.
Based on the total profile of UPR marker expression, 
the α2 strain shows the highest level of stress, suggesting 
that the low antibody yield from this strain might be due 
to a bottleneck in the secretory pathway. This correlates 
with the low levels of expression observed with ELISA 
for both total IgG1 and gp140 binding antibody. The copy 
number for α2 is the same as that for M1, which implies 
that the differences in volumetric productivity and secre-
tory stress are not due to copy number or a result of 
secretion saturation. Furthermore, while the light chain 
is capable of being secreted on its own, the heavy chain 
must be complexed with the light chain for secretion 
(Gasser et  al. 2006; Gach et  al. 2007; Lee et  al. 1999). 
Therefore, the limiting factor in intact antibody yield is 
the amount of heavy chain, which should theoretically be 
produced to higher amounts in α2 and M1 compared to 
α1 since two copies of the heavy chain have integrated.
For α1, on the other hand, the low yield could be 
explained by the fact that this is the only strain with a 
single copy of the heavy chain. In addition, there is a dis-
tinct lack of UPR upregulation. Although moderate levels 
of HAC1 splicing are observed 4  h after induction, this 
does not result in strong upregulation of chaperones or 
total HAC1 levels. It is possible that the levels of antibody 
produced by α1 are insufficient to activate UPR. Alterna-
tively, since the effects of UPR are known to have a posi-














































































































































Fig. 4 Changes in gene expression for elements of the UPR for VRC01 expressing strains. RT-qPCR was used to determine gene expression for 
KAR2, PDI¸ total HAC1 and spliced HAC1. ACT1 was used as the housekeeping gene. Fold change was calculated using the Pfaffl calculation, as a 
comparison to Δku70 0 h. Error bars are a representation of Gaussian error propagation from three technical replicates of three biological replicates. 
Red asterisks indicate a significant difference compared to Δku70 at 0 h, where p ≤ 0.05. a Spliced HAC1; b KAR2; c PDI1; d Total HAC1
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weak induction of UPR may perhaps explain the lower 
yield from α1 compared to the M1 and M2 strains.
Discussion
We have demonstrated successful expression of the bNAb 
VRC01 using P. pastoris as an expression platform with a 
signal sequence commonly used in mammalian expres-
sion vectors. It is the authors understanding that this is 
the first instance where the murine IgG1 signal peptide, 
which is commonly used in mammalian antibody expres-
sion vectors, has been used in P. pastoris. Although total 
volumetric productivities were not as high as has been 
reported for other full length antibodies (Ye et al. 2011), 
expression was carried out in shake flasks, and not bio-
reactors, and no growth optimisation was performed. 
Shah et al. recently described a high throughput method 
for constructing strains that express a range of anti-HIV 
bNAbs, with yields were between 100 and 500 ng mL−1, 
comparable to those shown here (Shah et al. 2015). Gas-
ser et al. saw no expression of either Fab or ScFV utilising 
the human secretion signal from 3D6 light chain (Gasser 
et  al. 2006). However, they also were not able to detect 
any antibody expression using the AOX1 promoter, sug-
gesting that differences in sequence or format may be the 
causes of differences.
Overall, the trends in the total and gp140 binding anti-
body yields from the ELISA data are comparable, i.e., 
strains with higher total antibody expression also have 
higher yields of specific binding antibody. The lower 
apparent yield of the antibody from the antigen-specific 
ELISA is likely due to different binding affinities of the 
antibody to the plate bound antigen in contrast to the 
much higher affinity capture ELISA used to detect total 
Ig. The plate bound antigen is distorted due to electro-
static stresses, leading to a reduction in the ability of 
the produced antibody to bind. Our results here with 
the antibody expressed in P. pastoris are identical to the 
binding seen with the same antibody produced in mam-
malian 293T cells, where the apparent antigen-specific 
yield is 1/20th–1/25th of that measured for the total Ig 
present (Additional file 4: Table S1).
The dot blot indicated that higher average yields were 
achieved in strains using the α-MF signal peptide. How-
ever, the ELISA results indicated that M1 and M2, which 
utilised the murine IgG1 signal peptide to direct protein 
to the secretory pathway, produced significantly higher 
yields of antibody than both the α1 and α2 strains. The 
discrepancy between the dot blot and ELISA results 
may be due to differences in the analytical techniques. 
The antibody used in the dot blot detects both light and 
heavy chains and therefore cannot distinguish between 
individual chains and intact antibody. Previous work has 
reported that the light chain can be secreted without 
dimerization to the heavy chain (Gasser et al. 2006; Gach 
et al. 2007; Lee et al. 1999), which can confound the dot 
blot results. In our total IgG ELISA procedure both the 
heavy and the light chain will be required to produce a 
signal because the antibodies are captured using anti-
bodies that bind to the light chain and detected using 
antibodies that bind the heavy chain thus ensuring both 
parts are present. In addition, the gp140 specific ELISA 
will require the correct conformation of the antibody as 
it captures based on antigen binding. This was supported 
by the Western blot analysis that indicates an imbalance 
of heavy and light chain between the strains (Additional 
file 3: Figure S3).
There have been previous reported instances where uti-
lising the α-MF as a signal sequence has not resulted in 
the highest yield (Lin-Cereghino et al. 2013; Ferrari et al. 
1997; Heiss et  al. 2015; Fitzgerald and Glick 2014). This 
phenomenon seems to be protein-dependent and dif-
ferent options are often examined during strain optimi-
sation. Our results suggest that the murine IgG1 signal 
peptide should be included among those options as it can 
be successfully utilised by P. pastoris to direct proteins to 
the secretory pathway.
The α-MF signal peptide from both the pPICZα and 
pJANs-1 vector contains EAEA repeats targeted for 
Ste13 cleavage (Brake et  al. 1984). It has previously 
been reported that removing this repeat region results 
in an increased homogeneity of N-terminal sequence of 
secreted proteins; however yields are reduced (Tanghe 
et  al. 2015; Kozlov and Yagudin 2008). Future analysis 
of the N-terminus of the antibody produced here may 
provide insights into the processing of the murine IgG1 
signal peptide, which does not have EA repeats and 
therefore should not be a substrate for STE13.
It would be interesting to determine whether the bene-
fits of using the murine IgG1 signal peptide reported here 
extend to monocistronic expression vectors. Both Gas-
ser et al. and Burtet et al. used a flexible linker to join the 
fragments to prevent uncoupled light chain from being 
secreted independently of the heavy chain (Burtet et  al. 
2007; Gasser et  al. 2006). Alternatively, a 2A sequence, 
which allows for multiple genes to be expressed simul-
taneously under the same promoter, could be used (Kim 
et  al. 2011; Shah et  al. 2015; Geier et  al. 2015). The 2A 
peptide functions co-translationally by causing a ribo-
some skip that cleaves between the glycine and final pro-
line (de Felipe et  al. 2006; Donnelly et  al. 2001; Trichas 
et al. 2008) to produce separate polypeptide chains. Uti-
lising a 2A sequence allows for more efficient process-
ing of the genes both upstream and downstream of the 
sequence and may also result in a reduced burden to the 
Page 9 of 11Aw et al. AMB Expr  (2017) 7:70 
cell, which may be beneficial for productivity and could 
improve the ratio of expression between the light and 
heavy chains (Shah et al. 2015; Geier et  al. 2015; Burtet 
et al. 2007).
In order to establish whether secretory stress on the 
strains resulted in differences of expression between 
those containing the α-MF signal peptide and those con-
taining the murine IgG1 signal peptide transcript levels 
of indicators of the UPR were evaluated. It was evident 
that the α2 strain was inherently sick, showing significant 
evidence of UPR signalling. The α1 strain, conversely, 
showed signs of a failure to upregulate UPR sufficiently 
to return to homeostasis, although this may be due to 
the single copy of the heavy chain integrated into the 
genome. Therefore, different underlying biochemistry is 
responsible for the lower yield in these two strains. The 
lower yields of the α strains may be a result of clonal 
variation, a well-established phenomenon in P. pastoris 
(Cregg et al. 1985; Schwarzhans et al. 2016), and have less 
to do with the utilisation of the α-MF over the murine 
IgG1 signal peptide. However, the strong results that we 
observed for the murine IgG1 signal peptide do indicate 
that achieving high yields are possible.
In summary, we have successfully expressed the bNAb 
VRC01 using P. pastoris and have shown that it is possible 
to utilise both the α-MF signal peptide and the murine 
IgG1 signal peptide for secretion. The highest concentra-
tion of total antibody obtained was 3.05 μg mL−1. Inter-
estingly, the levels of secretory stress appear reduced in 
the strains containing the murine IgG1 signal peptide 
and volumetric productivity was significantly increased 
for both strains compared to those utilising the α-MF sig-
nal peptide. Therefore, in the future, it would be useful 
to include the murine IgG1 signal peptide in expression 
optimisation experiments for antibodies, which could 
improve yield.
Additional files
Additional file 1: Figure S1. Confirmation of integration of heavy and 
light chains into P. pastoris. Colony PCR was used to confirm integration of 
both the independent light and heavy chains into P. pastoris.
Additional file 2: Figure S2. Copy number of heavy and light chains 
of α1, α2, M1 and M2. Copy number was determined by qPCR using a 
standard curve from plasmid DNA. Error bars are calculated using a Taylor 
series expansion for error propagation.
Additional file 3: Figure S3. Expression of VRC01 light and heavy chain 
in P. pastoris determined by Western Blot. Western blot was used to con-
firm the expression of both the light and heavy chains on a denaturing 
gel, using a secondary Rabbit Anti-Human IgG heavy and light antibody 
in both reducing and non-reducing conditions. A: reducing conditions; B: 
non-reducing conditions.
Additional file 4: Table S1. Calculated values for gp140-specific VRC01 
capture against starting concentration of VRC01. The results show 4–5% 
(1/20 to 1/25) binding capabilities.
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